Auris Medical Announces Clinical Results from AM-111 Phase 3 Clinical Trial

While the HEALOS trial had not met the primary efficacy endpoint in the overall study population, according to Auris, post-hoc analyses of top-line data revealed a clinically and statistically significant hearing improvement with AM-111 from baseline to Day 28 in the subpopulation of patients with profound hearing loss (n=98).